Emerging drugs for varicella-zoster virus infections

Bibliography

• Breuer J, Whitley R. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 2007;14(Suppl 2):25-9
   PubMedGoogle Scholar
• Gershon AA, Gershon MD, Breuer J, Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010;48(Suppl 1):S2-7
   PubMed Web of Science ®Google Scholar
• Beby-Defaux A, Brabant S, Chatellier D, Disseminated varicella with multiorgan failure in an immunocompetent adult. J Med Virol 2009;81(4):747-9
   PubMed Web of Science ®Google Scholar
• Anderson DR, Schwartz J, Hunter NJ, Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med 1994;154(18):2101-6
   PubMed Web of Science ®Google Scholar
• Lu YC, Fan HC, Wang CC, Cheng SN. Concomitant use of acyclovir and intravenous immunoglobulin rescues an immunocompromised child with disseminated varicella caused multiple organ failure. J Pediatr Hematol Oncol 2010; In press
   Web of Science ®Google Scholar
• Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol 2010;27(2):192-4
   PubMed Web of Science ®Google Scholar
• Zampogna JC, Flowers FP. Persistent verrucous varicella as the initial manifestation of HIV infection. J Am Acad Dermatol 2001;44(2 Suppl):391-4
   PubMed Web of Science ®Google Scholar
• Plisek S, Pliskova L, Bostik V, Fulminant hepatitis and death associated with disseminated varicella in an immunocompromised adult from the Czech Republic caused by a wild-type clade 4 varicella-zoster virus strain. J Clin Virol 2011;50(1):72-5
   PubMed Web of Science ®Google Scholar
• Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009;63(9):1386-91
   PubMed Web of Science ®Google Scholar
• Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010;9(3 Suppl):21-6
   PubMed Web of Science ®Google Scholar
• Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract 2010; In press
   PubMedGoogle Scholar
• Johnson RW, Bouhassira D, Kassianos G, The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37
   PubMed Web of Science ®Google Scholar
• Opstelten W, McElhaney J, Weinberger B, The impact of varicella zoster virus: chronic pain. J Clin Virol 2010;48(Suppl 1):S8-13
   PubMedGoogle Scholar
• Sanjay S, Huang P, Lavanya R. Herpes zoster ophthalmicus. Curr Treat Options Neurol 2011;13(1):79-91
   PubMed Web of Science ®Google Scholar
• Vafai A, Berger M. Zoster in patients infected with HIV: a review. Am J Med Sci 2001;321(6):372-80
   PubMed Web of Science ®Google Scholar
• Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol 2010; In press
   PubMed Web of Science ®Google Scholar
• Grossman MC, Grossman ME. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. J Am Acad Dermatol 1993;28(2 Pt 2):306-8
   PubMed Web of Science ®Google Scholar
• Mueller NH, Gilden DH, Cohrs RJ, Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 2008;26(3):675-97; viii
   PubMed Web of Science ®Google Scholar
• Hillenkamp J, Nolle B, Bruns C, Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology 2009;116(10):1971-5
   PubMed Web of Science ®Google Scholar
• Austin RB. Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management. Clin Eye Vis Care 2000;12(3-4):119-29
   PubMedGoogle Scholar
• Yin PD, Kurup SK, Fischer SH, Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 2007;38(3):254-9
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Mitchell SM, Barton K, Progressive outer retinal necrosis (PORN) in AIDS patients: a different appearance of varicella-zoster retinitis. Eye (Lond) 1995;9(Pt 3):271-6
   PubMedGoogle Scholar
• Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003;135(4):551-3
   PubMed Web of Science ®Google Scholar
• Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010;23(1):202-17
   PubMed Web of Science ®Google Scholar
• Vazquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005;352(5):439-40
   PubMed Web of Science ®Google Scholar
• Vazquez M. Varicella infections and varicella vaccine in the 21st century. Pediatr Infect Dis J 2004;23(9):871-2
   PubMed Web of Science ®Google Scholar
• Breuer J, Schmid DS. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis 2008;197(Suppl 2):S54-7
   PubMedGoogle Scholar
• Breuer J, Quinlivan M, Al Bassam M, DNA sequence variability in Oka vaccine isolates. J Infect Dis 2007;196(5):801-2
   PubMed Web of Science ®Google Scholar
• Loparev VN, Rubtcova E, Seward JF, DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 2007;195(4):502-10
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain 2008;9(1 Suppl 1):S31-6
   PubMed Web of Science ®Google Scholar
• Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010;27(2):159-76
   PubMed Web of Science ®Google Scholar
• Levin MJ, Gershon AA, Dworkin RH, Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol 2010;48(Suppl 1):S14-19
   PubMedGoogle Scholar
• Oxman MN, Levin MJ, Johnson GR, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84
   PubMed Web of Science ®Google Scholar
• Schmader KE, Johnson GR, Saddier P, Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 2010;58(9):1634-41
   PubMed Web of Science ®Google Scholar
• Elion GB, Furman PA, Fyfe JA, Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74(12):5716-20
   PubMed Web of Science ®Google Scholar
• Schaeffer HJ, Beauchamp L, de Miranda P, 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978;272(5654):583-5
   PubMed Web of Science ®Google Scholar
• Fyfe JA, Keller PM, Furman PA, Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253(24):8721-7
   PubMed Web of Science ®Google Scholar
• Keller PM, Fyfe JA, Beauchamp L, Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981;30(22):3071-7
   PubMed Web of Science ®Google Scholar
• Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255(15):7204-7
   PubMed Web of Science ®Google Scholar
• Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982;31(23):3879-84
   PubMed Web of Science ®Google Scholar
• Derse D, Cheng YC, Furman PA, Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem 1981;256(22):11447-51
   PubMedGoogle Scholar
• Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52(5):754-72
   PubMed Web of Science ®Google Scholar
• Darby G. Acyclovir–and beyond. J Int Med Res 1994;22(Suppl 1):33A-42A
   PubMedGoogle Scholar
• Weller S, Blum MR, Doucette M, Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54(6):595-605
   PubMed Web of Science ®Google Scholar
• Guo A, Hu P, Balimane PV, Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999;289(1):448-54
   PubMed Web of Science ®Google Scholar
• De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147(1):1-11
   PubMed Web of Science ®Google Scholar
• Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52(5):754-72
   PubMed Web of Science ®Google Scholar
• Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis 2004;39(Suppl 5):S258-66
   PubMed Web of Science ®Google Scholar
• DeJesus E, Wald A, Warren T, Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188(7):1009-16
   PubMed Web of Science ®Google Scholar
• Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28(4):281-90
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A, Patel R, Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350(1):11-20
   PubMed Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39(7):1546-53
   PubMed Web of Science ®Google Scholar
• Gupta R, Wald A, Krantz E, Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190(8):1374-81
   PubMed Web of Science ®Google Scholar
• Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995;50(2):396-415
   PubMed Web of Science ®Google Scholar
• Vere Hodge RA, Sutton D, Boyd MR, Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989;33(10):1765-73
   PubMed Web of Science ®Google Scholar
• Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31(8):1238-42
   PubMed Web of Science ®Google Scholar
• Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997;25(7):805-13
   PubMed Web of Science ®Google Scholar
• Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006;66(18):2397-416
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Loveless MO, Levin MJ, Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997;157(3):343-9
   PubMed Web of Science ®Google Scholar
• Sacks SL, Aoki FY, Martel AY, Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin Infect Dis 2005;41(8):1097-104
   PubMed Web of Science ®Google Scholar
• Wald A, Selke S, Warren T, Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33(9):529-33
   PubMed Web of Science ®Google Scholar
• De Clercq E, Descamps J, de Somer P, Walker RT. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci USA 1979;76(6):2947-51
   PubMed Web of Science ®Google Scholar
• De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004;68(12):2301-15
   PubMed Web of Science ®Google Scholar
• Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 1997;40(5-6):343-56
   PubMed Web of Science ®Google Scholar
• Desgranges C, Razaka G, De Clercq E, Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986;46(3):1094-101
   PubMed Web of Science ®Google Scholar
• Okuda H, Nishiyama T, Ogura K, Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25(2):270-3
   Web of Science ®Google Scholar
• Okuda H, Ogura K, Kato A, A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287(2):791-9
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Volpi A, McKendrick M, Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010;48(Suppl 1):S20-8
   PubMedGoogle Scholar
• Levy O, Orange JS, Hibberd P, Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003;188(7):948-53
   PubMed Web of Science ®Google Scholar
• Galea SA, Sweet A, Beninger P, The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008;197(Suppl 2):S165-9
   PubMed Web of Science ®Google Scholar
• Ota K, Kim V, Lavi S, Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatr Infect Dis J 2008;27(9):847-8
   PubMed Web of Science ®Google Scholar
• Uebe B, Sauerbrei A, Burdach S, Horneff G. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 2002;161(8):442-4
   PubMed Web of Science ®Google Scholar
• Fusco D, Krawitz P, LaRussa P, VZV meningitis following varicella vaccine. J Clin Virol 2010;48(4):275-7
   PubMed Web of Science ®Google Scholar
• Chouliaras G, Spoulou V, Quinlivan M, Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2010;125(4):e969-72
   PubMed Web of Science ®Google Scholar
• Pahwa S, Biron K, Lim W, Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988;260(19):2879-82
   PubMed Web of Science ®Google Scholar
• Snoeck R, Gerard M, Sadzot-Delvaux C, Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J Med Virol 1994;42(4):338-47
   PubMed Web of Science ®Google Scholar
• Boivin G, Edelman CK, Pedneault L, Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170(1):68-75
   PubMed Web of Science ®Google Scholar
• Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67(2):1024-33
   PubMed Web of Science ®Google Scholar
• Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5(2):88-114
   PubMed Web of Science ®Google Scholar
• Boivin G, Edelman CK, Pedneault L, Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170(1):68-75
   PubMed Web of Science ®Google Scholar
• Morfin F, Thouvenot D, Turenne-Tessier M, Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999;43(10):2412-16
   PubMed Web of Science ®Google Scholar
• Hatchette T, Tipples GA, Peters G, Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008;27(1):75-7
   PubMed Web of Science ®Google Scholar
• Safrin S, Berger TG, Gilson I, Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991;115(1):19-21
   PubMed Web of Science ®Google Scholar
• Bryan CJ, Prichard MN, Daily S, Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J 2008;27(10):946-8
   PubMed Web of Science ®Google Scholar
• Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 1998;178(Suppl 1):S55-7
   PubMedGoogle Scholar
• Fillet AM, Visse B, Caumes E, Clin Infect Dis 1995;21(5):1348-9
   Google Scholar
• Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 1999;59(1):84-90
   PubMed Web of Science ®Google Scholar
• Kamiyama T, Kurokawa M, Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 2001;82(Pt 11):2761-5
   PubMedGoogle Scholar
• Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004;61(3):181-7
   PubMed Web of Science ®Google Scholar
• Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31(8):1238-42
   PubMed Web of Science ®Google Scholar
• Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998;37(1):17-28
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kurokawa M, Yukawa TA, Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res 1995;27(3):271-9
   PubMed Web of Science ®Google Scholar
• Ida M, Kageyama S, Sato H, Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res 1999;40(3):155-66
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011;55(2):459-72
   PubMed Web of Science ®Google Scholar
• Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs 2002;3(11):1561-6
   PubMedGoogle Scholar
• Levin MJ, Dahl KM, Weinberg A, Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003;188(7):954-9
   PubMed Web of Science ®Google Scholar
• McGuigan C, Yarnold CJ, Jones G, Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 1999;42(22):4479-84
   PubMed Web of Science ®Google Scholar
• Srinivasan S, McGuigan C, Andrei G, Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain. Bioorg Med Chem Lett 2001;11(3):391-3
   PubMed Web of Science ®Google Scholar
• Brancale A, McGuigan C, Andrei G, Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain. Bioorg Med Chem Lett 2000;10(11):1215-17
   PubMed Web of Science ®Google Scholar
• Brancale A, McGuigan C, Algain B, Bicyclic anti-VZV nucleosides: thieno analogues retain full antiviral activity. Bioorg Med Chem Lett 2001;11(18):2507-10
   PubMed Web of Science ®Google Scholar
• McGuigan C, Pathirana RN, Jones G, Anti-varicella-zoster virus bicyclic nucleosides: replacement of furo by pyrro base reduces antiviral potency. Antivir Chem Chemother 2000;11(5):343-8
   PubMed Web of Science ®Google Scholar
• McGuigan C, Barucki H, Carangio A, Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000;43(26):4993-7
   PubMed Web of Science ®Google Scholar
• Balzarini J, McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 2002;1587(2-3):287-95
   PubMed Web of Science ®Google Scholar
• Andrei G, Sienaert R, McGuigan C, Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49(3):1081-6
   PubMed Web of Science ®Google Scholar
• McGuigan C, Pathirana RN, Migliore M, Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007;60(6):1316-30
   PubMed Web of Science ®Google Scholar
• Brancale A, Srinivasan S, McGuigan C, Synthesis and anti-varicella-zoster virus activity of some novel bicyclic nucleoside inhibitors: effect of enhanced aqueous solubility. Antivir Chem Chemother 2000;11(6):383-93
   PubMed Web of Science ®Google Scholar
• Sienaert R, Naesens L, Brancale A, Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002;61(2):249-54
   PubMed Web of Science ®Google Scholar
• Sienaert R, Naesens L, Brancale A, Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV). Nucleosides Nucleotides Nucleic Acids 2003;22(5-8):995-7
   PubMed Web of Science ®Google Scholar
• Balzarini J, Sienaert R, Liekens S, Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 2002;61(5):1140-5
   PubMed Web of Science ®Google Scholar
• Spector FC, Liang L, Giordano H, Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 1998;72(9):6979-87
   PubMed Web of Science ®Google Scholar
• Kleymann G, Fischer R, Betz UA, New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002;8(4):392-8
   PubMed Web of Science ®Google Scholar
• Baumeister J, Fischer R, Eckenberg P, Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother 2007;18(1):35-48
   PubMedGoogle Scholar
• Crute JJ, Grygon CA, Hargrave KD, Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002;8(4):386-91
   PubMed Web of Science ®Google Scholar
• Kleymann G. New antiviral drugs that target herpesvirus helicase primase enzymes. Herpes 2003;10(2):46-52
   PubMedGoogle Scholar
• Chen X, Adrian J, Cushing T, SAR studies on a novel series of human cytomegalovirus primase inhibitors. Bioorg Med Chem Lett 2007;17(8):2188-92
   PubMed Web of Science ®Google Scholar
• Cushing TD, Adrian J, Chen X, Discovery of a novel series of inhibitors of human cytomegalovirus primase. Bioorg Med Chem Lett 2006;16(18):4879-83
   PubMed Web of Science ®Google Scholar
• Chono K, Katsumata K, Kontani T, ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010;65(8):1733-41
   PubMed Web of Science ®Google Scholar
• Abele G, Eriksson B, Harmenberg J, Wahren B. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother 1988;32(8):1137-42
   PubMed Web of Science ®Google Scholar
• Lowe DM, Alderton WK, Ellis MR, Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother 1995;39(8):1802-8
   PubMed Web of Science ®Google Scholar
• De Clercq E, Naesens L, De Bolle L, Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001;11(6):381-95
   PubMed Web of Science ®Google Scholar
• Bonnafous P, Agut H. Activity of H2G on human herpesvirus-6B strains either sensitive or resistant to ganciclovir. J Clin Virol 2010;48(2):153-4
   PubMed Web of Science ®Google Scholar
• Ng TI, Shi Y, Huffaker HJ, Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother 2001;45(6):1629-36
   PubMed Web of Science ®Google Scholar
• Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998;42(12):3285-9
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr, Vezina HE, Hogquist RC, Randomized, placebo-controlled, double-blind trial of valomaciclovir (VALM) for infectious mononucleosis (IM) [abstract V1256a.:p221]. 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotheray; 14 September 2009; San Francisco, CA
   Google Scholar
• Visalli RJ, Fairhurst J, Srinivas S, Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol 2003;77(4):2349-58
   PubMed Web of Science ®Google Scholar
• Bloom JD, Dushin RG, Curran KJ, Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N′-arylthiourea inhibitors of CMV. Bioorg Med Chem Lett 2004;14(13):3401-6
   PubMed Web of Science ®Google Scholar
• Cardin RD, Bravo FJ, Sewell AP, Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol J 2009;6:214
   PubMedGoogle Scholar
• Bernstein DI, Goyette N, Cardin R, Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob Agents Chemother 2008;52(8):2727-33
   PubMed Web of Science ®Google Scholar
• Guzman EM, Cheshenko N, Shende V, Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir Ther 2007;12(8):1147-56
   PubMed Web of Science ®Google Scholar
• Vaillant A, Juteau JM, Lu H, Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob Agents Chemother 2006;50(4):1393-401
   PubMed Web of Science ®Google Scholar
• Matsumura T, Hu Z, Kato T, Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009;137(2):673-81
   PubMed Web of Science ®Google Scholar
• Kern ER, Prichard MN, Quenelle DC, Activities of certain 5-substituted 4′-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob Agents Chemother 2009;53(2):572-9
   PubMed Web of Science ®Google Scholar
• Prichard MN, Quenelle DC, Hartline CB, Inhibition of herpesvirus replication by 5-substituted 4′-thiopyrimidine nucleosides. Antimicrob Agents Chemother 2009;53(12):5251-8
   PubMed Web of Science ®Google Scholar
• Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs 2002;3(11):1561-6
   PubMedGoogle Scholar
• De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005;4(11):928-40
   PubMed Web of Science ®Google Scholar
• Xiong X, Smith JL, Kim C, Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996;51(11):1563-7
   PubMed Web of Science ®Google Scholar
• Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41(3):594-9
   PubMed Web of Science ®Google Scholar
• Beadle JR, Hartline C, Aldern KA, Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46(8):2381-6
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84-98
   PubMed Web of Science ®Google Scholar
• Hostetler KY, Rought S, Aldern KA, Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol Cancer Ther 2006;5(1):156-9
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2000;12(9-10):397-408
   PubMed Web of Science ®Google Scholar
• Snoeck R. Papillomavirus and treatment. Antiviral Res 2006;71(2-3):181-91
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41(3):587-93
   PubMed Web of Science ®Google Scholar
• Lebeau I, Andrei G, Krecmerova M, Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother 2007;51(6):2268-73
   PubMed Web of Science ®Google Scholar
• Hartline CB, Harden EA, Williams-Aziz SL, Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res 2005;65(2):97-105
   PubMed Web of Science ®Google Scholar
• Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003;63(3):678-81
   PubMed Web of Science ®Google Scholar
• Kern ER, Collins DJ, Wan WB, Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22
   PubMed Web of Science ®Google Scholar
• Bidanset DJ, Beadle JR, Wan WB, Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004;190(3):499-503
   PubMed Web of Science ®Google Scholar
• Wan WB, Beadle JR, Hartline C, Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005;49(2):656-62
   PubMed Web of Science ®Google Scholar
• Keith KA, Wan WB, Ciesla SL, Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother 2004;48(5):1869-71
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Collins DJ, Wan WB, Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(2):404-12
   PubMed Web of Science ®Google Scholar
• Ciesla SL, Trahan J, Wan WB, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59(3):163-71
   PubMed Web of Science ®Google Scholar
• Kern ER, Collins DJ, Wan WB, Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22
   PubMed Web of Science ®Google Scholar
• Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004;22(8):423-7
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84-98
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Aldern KA, Beadle JR, Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine. Antivir Chem Chemother 2006;17(2):89-95
   PubMedGoogle Scholar
• Ruiz JC, Beadle JR, Aldern KA, Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res 2007;75(1):87-90
   PubMed Web of Science ®Google Scholar
• Dal Pozzo F, Andrei G, Lebeau I, In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 2007;75(1):52-7
   PubMed Web of Science ®Google Scholar
• Beadle JR, Wan WB, Ciesla SL, Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem 2006;49(6):2010-15
   PubMed Web of Science ®Google Scholar
• Lebeau I, Andrei G, Dal Pozzo F, Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother 2006;50(7):2525-9
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84-98
   PubMed Web of Science ®Google Scholar
• De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007;75(1):1-13
   PubMed Web of Science ®Google Scholar
• Balzarini J, Pannecouque C, Naesens L, 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1321-7
   PubMed Web of Science ®Google Scholar
• Hockova D, Holy A, Masojidkova M, 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem 2003;46(23):5064-73
   PubMed Web of Science ®Google Scholar
• Hockova D, Holy A, Masojidkova M, Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem 2004;12(12):3197-202
   PubMed Web of Science ®Google Scholar
• De Clercq E, Andrei G, Balzarini J, Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;24(5-7):331-41
   PubMed Web of Science ®Google Scholar
• Krecmerova M, Holy A, Pohl R, Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J Med Chem 2007;50(23):5765-72
   PubMed Web of Science ®Google Scholar
• Krecmerova M, Holy A, Piskala A, Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 2007;50(5):1069-77
   PubMed Web of Science ®Google Scholar
• Krecmerova M, Holy A, Pohl R, Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J Med Chem 2007;50(23):5765-72
   PubMed Web of Science ®Google Scholar
• Topalis D, Lebeau I, Krecmerova M, Activity of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob Agents Chemother 2011;55(5):1961-7
   PubMed Web of Science ®Google Scholar
• Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002;50(6):779-92
   PubMed Web of Science ®Google Scholar
• Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 2006;17(6):293-320
   PubMedGoogle Scholar
• Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F. Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther 2010;7(1):7
   PubMedGoogle Scholar
• Orba Y, Sunden Y, Suzuki T, Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation. Virology 2008;370(1):173-83
   PubMed Web of Science ®Google Scholar
• Schang LM. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev Anti Infect Ther 2006;4(6):953-6
   PubMedGoogle Scholar
• Yang H, Kim SK, Kim M, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005;115(2):379-87
   PubMed Web of Science ®Google Scholar
• Reeves PM, Bommarius B, Lebeis S, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11(7):731-9
   PubMed Web of Science ®Google Scholar
• Rowe J, Greenblatt RJ, Liu D, Moffat JF. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res 2010;86(3):276-85
   PubMed Web of Science ®Google Scholar
• Messaoudi I, Barron A, Wellish M, Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans. PLoS Pathog 2009;5(11):e1000657
   PubMed Web of Science ®Google Scholar